Dudum is still the largest individual holder of Hims & Hers’ stock, owning about 8 million shares indirectly through various ...

Telehealth company Hims & Hers Health (NYSE:HIMS) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 72.6% year on year to $544.8 million. On the other hand, the company expects ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

The telehealth and wellness stock tanked more than 12% Aug. 5, a day after posting mixed Q2 earnings. More importantly, Bank ...

Hims & Hers has been an incredible stock to own over the last few years, making shareholders rich. It has $2 billion in ...

Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending ...

In response to this news, Hims shares plummeted by nearly 26%. Since then, the company has been working to figure out how to continue growing its successful weight loss drug business.

Hims & Hers: New Weight Loss Category Is A Prescription For Explosive Growth And Upward Revisions Dec. 18, 2023 6:38 AM ET Hims & Hers Health, Inc. (HIMS) Stock HIMS 4 Comments ...

Health platform Hims & Hers Health Inc. announced Monday that it's rolling out injectable weight-loss drugs that cost a fraction of the price of competitors Wegovy and Ozempic.

Hims is far from finished in weight-loss drugs. The company aims to offer compounded tirzepatide, the active ingredient in Lilly’s Mounjaro and Zepbound, in the next couple of months.